Safety and Tolerability of Tedizolid as Oral Treatment for Bone and Joint Infections
Results. To date, we have enrolled 19 subjects (17 (89%) male) with BJIs (11 (58%) hardware associated infection, 5 (26%) osteomyelitis without prosthesis, 3 (16%) prosthetic joint infection). Significant comorbidities include six (32%) with diabetes and one (5%) with systemic lupus. Fourteen (74%) patients have completed therapy, two (11%) remain on therapy, one (5%) withdrew from the study, and two (11%) were lost to follow-up. Mean (median) duration of treatment has been 9.7 (11) weeks with a range of 4-12 weeks. Significant drug-related adverse events occurred in two patients (11%), both with non-life-threatening maculopapular rashes, one of whom required treatment discontinuation. To date, there have been 10/14 (71%) treatment successes. Failures have been associated with previously undetected retained hardware (n = 1), sequestrum requiring surgery (n = 1), and failure to achieve cure after the designated treatment course (n = 2). There have been no cases of cytopenias, peripheral or optic neuropathy.
Conclusion. Tedizolid appears to be a well-tolerated oral antibiotic for the treatment of bone and joint infections for 4 weeks or greater. Clinical failure rates appear roughly similar to that of other oral options. Further study of tedizolid for BJIs is warranted.
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